These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 9269253)

  • 1. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor and mental side effects of clozapine.
    Gerlach J; Peacock L
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():107-9. PubMed ID: 7961551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients?
    Levin H; Chengappa KN; Kambhampati RK; Mahdavi N; Ganguli R
    J Clin Psychiatry; 1992 Jul; 53(7):248-51. PubMed ID: 1353492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I.
    van Harten PN; Matroos GE; Hoek HW; Kahn RS
    Schizophr Res; 1996 May; 19(2-3):195-203. PubMed ID: 8789918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
    Jung HY; Kim JH; Ahn YM; Kim SC; Hwang SS; Kim YS
    Hum Psychopharmacol; 2005 Jan; 20(1):41-5. PubMed ID: 15565639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J; Dwolatzky T; Brettholz I; Lerner V
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Schizophr Res; 1997 Aug; 26(2-3):235-42. PubMed ID: 9323356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between akathisia or Parkinsonism and suicidality in treatment-resistant Schizophrenia.
    Hansen L; Jones RM; Kingdon D
    J Psychopharmacol; 2004 Sep; 18(3):384-7. PubMed ID: 15358982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
    Barnes TR; McPhillips MA
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of antipsychotic drugs.
    Malhotra AK; Litman RE; Pickar D
    Drug Saf; 1993 Dec; 9(6):429-36. PubMed ID: 7907481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Schizophr Res; 1991; 4(2):109-20. PubMed ID: 1674881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of tardive dyskinesia and tardive dystonia.
    Simpson GM
    J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.